Accurate Mammogram Reading More Likely Following Mammotome Biopsy, Study Indicates

Publication
Article
OncologyONCOLOGY Vol 12 No 7
Volume 12
Issue 7

Mammotome biopsy causes significantly less internal breast scarring than open surgical biopsy and is less likely to interfere with a radiologist’s ability to read subsequent mammograms, according to a new study presented at the third annual

Mammotome biopsy causes significantly less internal breast scarring than open surgical biopsy and is less likely to interfere with a radiologist’s ability to read subsequent mammograms, according to a new study presented at the third annual Multidisciplinary Symposium on Breast Disease in Amelia Island, Florida, a medical conference of radiologists and surgeons specializing in breast disease.

The study indicates that, compared to Mammotome biopsy, internal scarring from open surgical breast biopsy is more than twice as likely to influence the radiologist’s ability to read a subsequent mammogram. Researchers also found that open surgical biopsy caused nearly twice as much internal scarring as did Mammotome biopsy.

Scarring and Mammography

The study suggests that women who have open surgical biopsy are more likely to develop changes on future mammograms than are women who have had a Mammotome biopsy, said lead author Catherine A. Kusnick, MD, assistant professor of radiology at the University of Iowa College of Medicine. These changes may require additional mammographic evaluation on future mammograms.

Scarring from open surgical biopsy influenced the confidence level in reading mammograms in more than 72% of cases studied. In contrast, Mammotome biopsy influenced the confidence level in only 29.5% of cases studied.

"This is a significant improvement. Post biopsy scarring can sometimes mimic or mask subtle breast cancers. The reduced rate of scarring from Mammotome biopsy compared to surgical biopsy may make it easier for radiologists to read future mammograms," said Dr. Kusnick.

Researchers identified scarring on one-half of mammograms following open surgical biopsy, as compared with only 27.3% of mammograms following Mammotome biopsy.

The study involved five radiologists specializing in mammography but with different experience levels, who were blinded to biopsy technique, breast lesion location, and identifying features. The radiologists examined two sets of mammograms, 14 surgical and 19 Mammotome cases. Even with the relatively small number of cases, the methodology and findings indicate significant statistical accuracy for the study, Dr. Kusnick said.

Minimally Invasive

Mammotome biopsy allows women to have a quick, minimally invasive breast biopsy. During the half-hour, outpatient procedure, the physician inserts a sampling probe through a small nick in the patient’s breast, which does not have to be repeatedly removed and inserted. Following the biopsy, the patient goes home with a small adhesive strip to cover the skin nick.

Open surgical biopsy, by comparison, is a more costly, time-consuming process that requires anesthesia, an operating room, and sutures.

Related Videos
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
Related Content